This volume explores the mechanisms of resistance to targeted therapeutics. The focus is on the cancer cell signaling network, although other mechanisms of resistance including target mutation, and new areas of study such as cancer stem cells are included. Targeted Therapies: Mechanisms of Resistance highlights examples of changes in the signaling network in response to inhibition of a signaling event and underscores the importance in having a mechanistic understanding of the signaling network in cancer for developing effective targeted cancer therapies. Moreover, cutting edge tools to analyze the cell signaling network will be discussed. This includes the leading edge of techniques as well as computational biology and systems theory. This volume provides the reader with both an overview as well as a detailed perspective on the mechanisms of resistance to targeted therapeutics and will be of great value to the oncologist, the physician-scientist treating patients and the translational scientist working on any aspect of targeted therapeutics.

In this book we have taken a comprehensive look at the subject of familial and hereditary gastric tumors. In particular, the aim of this novel editorial work is to propose the correct management of hereditary diffuse gastric cancer patients, focusing in particular on E-cadherin germline mutations, clinical criteria definition, genetic screening and molecular mechanisms, pathology and microscopic features, surgical treatment and clinical approach for asymptomatic mutation carriers. We also describe other inherited predispositions involving gastric carcinoma.

Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances brings together the three main pelvic specialties (Urology, Gynecological Oncology and Colorectal Surgery) into one volume. Patients have been shown to benefit from a multidisciplinary approach since it allows surgeons of different specialties to learn from one another therefore enhancing the treatment for the patient. Pelvic cancer outcomes are poor in low volume centres. These centres account for 80% of the global centres dealing with these cancers. Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances is a much needed book that can focus training and assist health professionals in their care of patients with pelvic dysfunction. Pelvic Cancer Surgery: Modern Breakthroughs and Future Advance is complete with full color illustrations and schematic diagrams and makes use of key points and stepwise figures for an enhanced learning experience.

This book is a detailed, accessible and comprehensive reference manual reflecting current guidance & citing recent peer-reviewed evidence. It is written by and for radiographers. Through text and diagrams the fundamental skills and techniques for acquisition of high quality diagnostic images are explained and demonstrated; high quality ultrasound images throughout underpin instruction on accurate image interpretation and diagnosis. Inclusion of unusual and rare appearances allow the reader to avoid common pitfalls and resolve diagnostic dilemmas. The inclusion of clinical and pathological information gives the book an holistic outlook and wider appeal to those not specifically interested in practical instruction. The author has expertise and current experience in clinical practice and educational delivery and focuses on application of theory to practice giving step-by-step practical guidance with clear, concise and structured content. Ultrasound & mammography practitioners in training can use this book to underpin practical and theoretical instruction to achieve success on formal education programmes; practising medical and non-medical health care professionals continue to refer to a departmental shelf copy as an authoritative reference text to inform and improve the quality of their everyday clinical practice and service to patients. Step-by-step guide to performing, interpreting and reporting breast ultrasound examinations Extensive coverage of underlying principles and practice of breast ultrasound Holistic chapter on ultrasound of the male breast Experienced editor and contributing team with current experience in clinical practice and educational delivery Application specific physics and equipment chapters

Combined modularized therapies for metastatic cancer are pointing to central problems of communication among 'systems participators'. A communication theory explains 'social engineering', endogenously induced or by implementing non-normative boundary conditions. Evolution-adjusted tumor pathophysiology is borne by an evolution theory, which contrasts narrative evolution histories. The tool of rationalizations constituting the tumor's normativity (inflammation, immune response etc.) represents the non-genomic counterpart of the tumor genome and should be additionally assessed during tumor staging. Evolution-adjusted tumor pathophysiology allows implementing applied systems biology, a novel clinical and pharmaceutical technology for bioengineering tumor response and personalizing tumor therapy. Combined modularized therapy, evolution-adjusted tumor pathophysiology, and 'universal' biomarkers concertedly address genetically based tumor heterogeneity.

While many comprehensive texts have been written on the treatment of breast cancer, the most common cancer among women, there are relatively few which cover in depth the prevention and early detection of the disease. The goal of this work is to present what experts in the ?eld feel is the current knowledge and future direction of breast cancer prevention and early detection. We begin Part I of the book with a review of risk factors, both genetic and environmental. We next review progress in the use of chemoprevention. Notably, chemoprevention risk reduction studies have led to FDA approval of two medications which measurably reduce disease incidence among women at increased risk, although with some risk of treatment related side effects. Newer agents in the pipeline, which may also reduce risk among normal risk women, are also discussed. Surgical risk reducing strategies complete the section on prevention, including both the bene?ts and downsides to this more aggressive approach. Even with aggressive prevention strategies, some women will develop breast cancer. For these women, early detection is critical to minimize disease spread and maximize long term survival. Part II of this book reviews current and upcoming approaches to early detection. Imaging strategies, including mammography, breast ultrasound, MRI, and PET imaging are reviewed. The potential for molecular tumor targeting to detect disease prior to the formation of a mass visible by anatomic imaging is presented.

This book covers the scope of current knowledge of cancer in the LGBT community across the entire cancer continuum, from understanding risk and prevention strategies in LGBT groups, across issues of diagnosis and treatment of LGBT patients, to unique aspects of survivorship and death and dying in these communities. Each chapter includes an in depth analysis of the state of the science, discusses the many remaining challenges and unanswered questions and makes recommendations for research, policy and programmatic strategies required to address these. Focus is also placed on the diversity of the LGBT communities. Issues that are unique to cancer in LGBT populations are addressed including the social, economic and cultural factors that affect cancer risk behaviors, barriers to screening, utilization of health care services, and legislation that directly impacts the health care of LGBT patients, healthcare settings that are heterosexist and unique aspects of patient-provider relationships such as disclosure of sexual orientation and the need for inclusion of expanded definition of family to include families of choice. The implications of policy change, its impact on healthcare for LGBT patients are highlighted, as are the remaining challenges that need to be addressed. A roadmap for LGBT cancer prevention, detection, diagnosis, survivorship, including treatment and end of life care is offered for future researchers, policy makers, advocates and health care providers.

Lymphomas are lymphoid malignancies derived from B or T lymphocytes, and their study has been and still is paradigmatic for many aspects of cancer research. Lymphoma: Methods and Protocols presents and discusses key methods that are used in lymphoma research, partly specific for lymphoma research but often adaptable to the study of other cancers. By covering a broad variety of methods used in lymphoma research, this book will be of interest not only for hematologists, hematopathologists, and immunologists but also for scientists interested in other fields of cancer research as well as human genetics. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Versatile and cutting-edge, Lymphoma: Methods and Protocols serves researchers studying human physiology with the ultimate goal of understanding and controlling these often terrible diseases.

Numerous studies have shown that elevated levels of circulating tumor cells (CTCs) in blood of cancer patients are associated with poor response to treatment and inferior survival probabilities. Despite this clinical significance, the molecular biology of CTCs remains poorly understood. The paucity in molecular information can be attributed to the tremendous technical challenges involved in isolating these extremely rare cells. Recent technological advancements in rare-cell technology, however, have allowed for the reliable enrichment and isolation of CTCs. Consequently, the use of recently developed molecular approaches -e.g., multiplexed QPCR, microarray, and next generation sequencing analyses- to profile CTCs have provided novel insights into the molecular makeup of these tumor cells. This book discusses approaches for enrichment and isolation of CTCs as well as recent advances in comprehensive molecular profiling of CTCs using cutting-edge omics technology.

This is the first volume to provide a multidisciplinary approach to peritoneal carcinomatosis encompassing molecular mechanisms, histopathology, regional and systemic cytotoxic therapy, and surgical options. Illustrations aid the reader throughout in the many facets of this disease. The book will be of particular interest for medical, surgical and gynecological oncologists faced with the complexities of decision making in patients suffering from PC.

This book discusses the molecular, biological, pathological, and clinical aspects of melanoma, with special emphasis in the new concepts of melanoma genetics. A multidisciplinary group of experts in Genetics, Dermatology, Pathology, and Melanoma Medical Oncology contribute state-of-the-art knowledge in melanoma research and clinical management, not only exposing the current status of knowledge of the topics but also providing their personal experiences and ideas about the future and potential practical application of the genetic aspects of melanoma. During the last few years we have witnessed an impressive amount of discoveries in the field of melanoma genetics which have changed our approach in understanding the pathogenesis and treatment of this lethal disease. Genetics of Melanoma is a practical approach to melanoma genetic mechanisms and their application in the diagnosis and treatment of this malignancy. It is an essential source of updated information and a powerful tool for clinicians, pathologists, and basic scientists who wish to understand, apply, and investigate the multiple new aspects of melanoma genetics.

Sphingolipids are lipid components of the plasma membrane in eukaryotic cells. They have an important function in signaling mechanisms in the cell. This book on sphingolipids provides insights into the basics of sphingolipid biology and drug development, with a particular emphasis on the sphingolipid derivative ceramide. In the first part basic functions of sphingolipids are described, as well as the genetics of important enzymes, sphingolipid metabolism and synthesis. The second part of this first volume focuses on drug development and pharmacology. The book is intended for scientists in pharmacology, biochemistry and cell biology with a focus on biomedical research as well as for clinicians working in pharmacology, oncology, cardiology, neurology and infectious disease. Together with Volume 216 by the same editors, the collection represents a unique, comprehensive work on sphingolipids, providing information on both sphingolipids basic biology (including synthesis, metabolism and cell biology) and their important function in a (patho-)physiological context."

There is extremely compelling evidence to suggest that if people are physically active before, during and after cancer treatment, their outcomes are likely to be better. Their risk of recurrence (and death) is lower and their ability to deal with the myriad side effects is improved significantly. Increasingly people with cancer understand this but they are often unsure of what exercise would be best, what is safest, what would be most effective and what to avoid. This book offers very practical, targeted information to enable people to exercise in whatever way they feel ready for. It provides guidance on effective and appropriate exercise for anybody who has received a diagnosis of cancer, including those receiving active treatment and those living with incurable cancer of all types, with the emphasis on the proven benefits of exercise and activity.

The American Cancer Society recently estimated that about 45,000 new cases of thyroid cancer will be diagnosed in the United States, with three-quarters occurring in women. The overall 5-year survival rate is about 97%, making it one of the least lethal cancers. We are experiencing an epidemic of well-differentiated thyroid cancer, in part due to the widespread use of imaging modalities that detect thyroid nodules and microcarcinomas. Concurrently, there have been a number of recent advances in surgical treatment, as well as diagnostic modalities that allow us to detect small amounts of residual local and metastatic disease. Additionally, a reexamination of past treatment regimens has led to new recommendations regarding the use of radioactive iodine, and to new therapeutic options, such as targeted therapy which have supplanted the use of more toxic chemotherapy for metastatic cancer. Multiple academic organizations have developed consensus guidelines for the management of thyroid cancer, occasionally with conflicting recommendations. In Thyroid Cancer, a renowned group of authors presents a broad overview of the pathology, pathophysiology, diagnosis, and management of thyroid cancer, with an emphasis on recent evidence-based information. State-of-the-art and a significant contribution to the literature, Thyroid Cancer is an invaluable reference for endocrinologists, oncologists, nuclear medicine physicians, radiation oncologists, primary care physicians, and surgeons who deal with head and neck cancer.

This volume focuses on defining the unique attributes of using the zebrafish cancer model for discovering important pathways and potential drug targets for the treatment of human cancers. Using the zebrafish model, the volume explores oncogene and tumor suppressor discovery, chemical genetic approaches, genomics, epigenetics, cancer imaging, and cell transplantation. Contributed chapters come from the most prominent laboratories working in this field, which provides a unique perspective on zebrafish models from a wide spectrum of the research community. In addition, the book offers a detailed analysis of the most current research in the area for specific zebrafish cancer models, including T cell leukemia, rhabdomyosarcoma, liver and pancreatic cancer, melanoma, neuroblastoma, germ cell tumors, and malignant peripheral sheath tumors. A chapter is also dedicated to the development and utilization of other piscine models of cancer. The compilation of chapters in the volume culminates into a comprehensive and definitive text on zebrafish and cancer, providing a much needed resource on the powerful attributes of the zebrafish model system.

This topical volume provides an overview of clinically relevant data on anticancer agents. It is not only intended medical doctors working with cancer patients, and for medical researchers and students. The different classes of anticancer drugs are described by international authorities on the various topics. Apart from new targets for anticancer agents, attention is also focused on improving efficacy and tolerability of existing compounds.

Over the past 10 years, work on acute promyelocytic leukemia (APL) has become the paradigm of translational research that began with the discovery of a recurrent chromosomal translocation, followed by the identification of the genes and proteins involved, finding their molecular functions in transcriptional control, establishing mouse models and culminating in the development of targeted therapy.

This book addresses the most pressing current questions in the management of urologic malignancies. The rapid advances in imaging and molecular markers are placed into a clinical context, with explanation of their effects on prognosis and treatment planning. Similarly, progress in immunotherapy is carefully examined, focusing in particular on the role of immune checkpoint inhibitors in both early- and late-stage urologic malignancies. Looking beyond the improvements in minimally invasive techniques for urologic cancers, the impacts of care coordination pathways and enhanced recovery after surgery protocols are reviewed. Readers will also find enlightening discussion of the decision algorithm for the treatment of early-stage, high-grade bladder cancer, taking into account evidence on the most advanced treatment options and the circumstances in which surgery may need to be expedited. The penultimate chapter discusses the Cancer Genome Atlas project for bladder cancer, and the book closes by considering contemporary medical and surgical management of testicular cancer.

Detection and characterization of bone tumors with imaging remains a big challenge for every radiologist notwithstanding the impressive progress achieved by the introduction of several new imaging modalities. Moreover, new concepts in surgical and oncological treatment of these lesions require from the radiologist appropriate and focused answers to the specifc questions asked by the referring physicians in order to choose the best therapeutic approach for the in- vidual patient. Tis comprehensive textbook describes in detail the possibilities and limits of all moda- ties, including MRI, CT, nuclear medicine and interventional radiological procedures, employed for the modern imaging of tumoral and tumor-like lesions of bone. Teir role in the diagnosis, surgical staging, biopsy and assessment of response to therapy is discussed in detail, covering all tumor subtypes as well as their specifc anatomical location.Well selected and technically imp- cable illustrations strongly enhance the didactic value of this work. I am very much indebted and grateful to the three editors: A. Mark Davies, Murali Sundaram and Steven L. J. James, world authorities in musculoskeletal radiology, for their superb scientifc achievement in preparing and editing this wonderful volume as well as for their individual ch- ters. I would also like to thank the large international group of collaborating authors, who are also widely acknowledged for their specifc expertise in the area of bone tumors, for their outstanding contributions.

Is cancer a systemic disease? Does regional nodal metastases instigate distant metastasis or promote failure at the primary site? These are just two of the issues discussed in this new volume based on the results of a symposium on the diagnosis, significance and treatment of occult regional nodal metastases in the most common types of cancer. Occult Nodal Metastasis in Solid Carcinomata presents material for all levels of interest--from basic science to clinical application, and will be of practical use to medical libraries, oncologists, radiologists, clinical pathologists, immunologists, and cell and molecular biologists.

The mature T and NK cell lymphomas are rare, comprising approximately 10% of all malignant lymphomas. The incidence of T- cell lymphoma is variable around the world, with a higher incidence compared to B-cell lymphomas in the Asian basin. While the overall incidence of B-cell lymphomas has begun to decline in the United States, the incidence of T-cell lymphomas continues to rise. Over the last decade, a number of novel agents have been developed which target T-cell lymphomas and studies have identified novel genes and pathways associated with lymphomagenesis in T-cells. This comprehensive volume examines the clinical and biological aspects of the T-cell lymphoproliferative disorders in adults and children. The book includes an overview of both the cutaneous and the systemic T-cell malignancies and addresses the classification of T-cell lymphomas, the clinical features of each subtype, and the relevant molecular and genetic studies. Clinical outcomes and treatment strategies are discussed with an emphasis on the development of novel biological and targeted therapies. An outstanding resource for hematologists and oncologists, this book gathers insights from experts in the field and provides the most up-to-date information on all of the T-cell lymphoma subgroups and current and emerging therapies.